We are proud to announce the following international and national invited faculty for the 2019 SABR Symposium.
Professor Dr. Matthias Guckenberger is the Chairman of the Department for Radiation Oncology, University Hospital Zurich (USZ). Development, clinical implementation and evaluation of advanced imaging, planning and delivery technologies into radiotherapy treatment has been a major research focus, especially stereotactic body radiotherapy (SBRT) for early stage NSCLC and oligo-metastatic disease. Modelling of tumor and normal tissue response to radiotherapy has been another focus. Overall, research has been published in>200 peer-reviewed articles.
Dr. Cliff Robinson is an Associate Professor of Radiation Oncology and Cardiology at Washington University in St. Louis, where he serves as Chief of the Thoracic and Stereotactic Body Radiotherapy services and Director of Clinical Trials. He is co-chair on two cooperative group protocols (NRG BR001, LU002) exploring the safety and efficacy of SBRT as an adjunct to systemic therapy for metastatic cancer, and PI of a worldwide industry-sponsored trial comparing SBRT with or without immunotherapy for early stage lung cancer (PACIFIC-4). Most recently, he has collaborated with Cardiology in the development of a novel, totally noninvasive treatment for arrhythmia using SBRT, with initial outcomes published in the New England Journal of Medicine.
Dr. Carri Glide-Hurst obtained her PhD in Medical Physics from Wayne State University (WSU) in 2007 and then spent two years in postdoctoral training at William Beaumont Hospital. She has since been at Henry Ford Health System, where she is Director of Translational Research and Associate Professor at WSU. Her primary focus includes implementation of MR-SIM and MR-guided radiation therapy including stereotactic body and adaptive radiation therapies on one of the first clinical MR-linacs in the world. Dr. Glide-Hurst was awarded an NIH R01 on MR-only Treatment Planning and is PI/Co-PI on 11 other grants. She has published 55 manuscripts, 7 book chapters, >150 abstracts, holds 2 patents, and is a Fellow of the AAPM. She serves on 9 AAPM committees, most notably Co-chair of TG-284 on MR simulation and Annual Meeting Scientific Track Director. She is active at ASTRO, ARS, and the ABR and is leading efforts at NRG to integrate ART into national clinical trials. Dr. Glide-Hurst is most passionate about mentoring future physicists and trainees, especially women in STEM, in their research careers.
Paul Keall is a Professor in the Sydney Medical School, an NHMRC Senior Principal Research Fellow and the Director of the ACRF Image X Institute at the University of Sydney. His team of scientists, clinical partners and international collaborators create, share and apply novel cancer imaging and targeted radiotherapy methods. He was the Director of the Radiation Physics Division at Stanford University (2006-2010) where he was charged with leading the academic, clinical and educational missions of 70 academic and clinical staff. In 2010 he was awarded the prestigious Australia Fellowship and recruited to the University of Sydney. Outputs from his research include multiple bench-to-bedside clinical trials, 300+ scientific publications, 18 patents, 8 licenses and three start-up companies. His work is funded primarily by competitive government research grants and he works closely with industry to apply his research output, and has 25 current and completed industrial research agreements
Dr. Alex Louie is a a Radiation Oncologist at the Odette Cancer Centre, Sunnybrook Health Sciences Centre, an Ontario Association of Radiation Oncology Clinician Scientist at the University of Toronto, and a Scientist at the Sunnybrook Research Institute. Prior to starting at Sunnybrook, he practiced as a Radiation Oncologist at the London Regional Cancer Program, Western University for 4 years. Dr. Louie holds a BSc and MD from Western University, a Master’s Degree in Epidemiology from the Harvard School of Public Health, and a PhD (Cum Laude) in lung SABR from the VU University Medical Center, Netherlands. He is an IC/ES Faculty Scholar and an IASLC Academy Young Investigator. Dr. Louie is actively involved in ASCO’s Clinical Practice Guidelines Implementation Network; ASTRO’s Education, Scientific and Guideline committees; and the Ontario Cancer Research Ethics Board. He has authored nearly 100 peer-reviewed manuscripts, and his research focuses on the use of comparative effectiveness of radiotherapy for lung, kidney and oligometastatic cancers.